Nuvation Bio Inc SEC Filings

A shareholder of NUVB has filed a Rule 144 notice to sell up to 369,051 common shares through broker Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of 2,667,131.58 for these shares, compared with 342,833,433 common shares outstanding. The shares come from the exercise of stock options under a registered plan, with lots of 300,000 and 69,051 options exercised for cash on 11/20/2025. The notice also discloses that Gary Hattersley sold 100,000 common shares for gross proceeds of 502,460.00 on 10/27/2025 during the prior three months.

An affiliate of NUVB has filed a Form 144 notice to sell 20,000 shares of Class A common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $140,074.00. The filing lists 342,833,433 shares of Class A common stock outstanding and shows that the 20,000 shares were acquired on 11/20/2025 by exercising options under a registered plan for cash. The seller, Dongfang Liu, also sold 15,000 Class A shares on 11/17/2025 and 15,000 shares on 11/19/2025 in the prior three months.

Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer on Form 4. On 11/17/2025 and 11/19/2025, the officer exercised stock options to buy a total of 30,000 shares of Class A common stock at an exercise price of $1.87 per share and sold 30,000 shares in open-market transactions.

The sales included 15,000 shares on 11/17/2025 at $4.765 per share and 15,000 shares on 11/19/2025 at a weighted-average price of $5.1035 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock and held 470,000 stock options with a $1.87 exercise price expiring on 02/27/2034.

NUVB shareholder files notice to sell common shares under Rule 144. A holder of Class A common stock plans to sell 15,000 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $76,552.50. These shares were acquired on 11/19/2025 by exercising options under a registered plan for cash and will be sold as freely tradable stock. The notice also reports a prior sale over the past three months of 15,000 Class A common shares on 11/17/2025 for gross proceeds of $71,475. The form includes a representation that the selling holder is not aware of any undisclosed material adverse information about NUVB’s operations.

NUVB Form 144 shows a planned insider sale of common stock. A holder has filed notice to sell 200,000 shares of Nuvation Bio common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,427,680.00. The shares are listed for sale on the NYSE with an approximate sale date of 11/19/2025. As of the filing, 342,833,433 shares of Nuvation Bio common stock were outstanding, which is a baseline figure for the company’s equity. The shares to be sold were acquired on 11/19/2025 by exercising stock options under a registered plan and paid for in cash.

Nuvation Bio Inc. released an updated corporate presentation and highlighted newly published positive Phase 2 data for its IDH1 inhibitor safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. In an open-label study of 27 patients, safusidenib achieved an objective response rate of 44.4%, and median duration of response was not yet estimable because no progression had occurred. As of the data cut-off on March 10, 2023, median progression-free survival had not been reached, with 87.9% of patients progression free at 24 months and median follow-up of 28 months, suggesting durable disease control.

Adverse events were mostly mild to moderate; grade 3 or higher treatment-related events occurred in 18.5% of patients, with no grade 5 events and 11.1% discontinuations. A Good Clinical Practice noncompliance issue in adverse event collection was addressed through re-investigation and re-collection of safety data. Nuvation Bio is advancing the G203 global randomized study of safusidenib as maintenance therapy in high-grade and high-risk grade 2 IDH1-mutant gliomas, with a protocol amendment to finalize it as a global Phase 3 trial. The primary endpoint is progression-free survival by blinded central review, which the U.S. Food and Drug Administration has agreed could support full approval.

NUVB filed a Form 144 notice for a proposed sale of its Class A common stock. The filing covers a planned sale of 15,000 Class A common shares on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $71,475. These 15,000 shares were acquired on 11/17/2025 by exercising stock options under a registered plan, paid for in cash on the same date. The filing notes that 342,833,433 shares of Class A common stock were outstanding, providing context for the size of the planned sale.

Nuvation Bio (NUVB) reported Q3 2025 results. Total revenue was $13.1 million versus $0.7 million a year ago, driven by the first commercial sales of IBTROZI in the U.S. Product revenue was $7.7 million, and collaboration and license revenue was $5.4 million. Cost of revenue was $3.3 million, yielding gross profit of $9.8 million.

Operating expenses were $66.2 million (R&D $28.8 million; SG&A $37.4 million). Loss from operations was $56.4 million and net loss was $55.8 million ($0.16 per share). Weighted average shares outstanding were 342.4 million.

Liquidity remained significant with $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025. During the nine months, the company received $150.0 million from a revenue interest financing agreement and $48.9 million in borrowings; operating cash outflow was $143.7 million. Total liabilities rose to $275.7 million, including $150.6 million related to the revenue interest financing and $47.1 million in long-term borrowings. IBTROZI began U.S. shipments in June 2025.

Nuvation Bio Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and, along with the related information, is furnished rather than filed under the Exchange Act and Securities Act, except as specifically incorporated by reference. The company’s Class A Common Stock (NUVB) and Redeemable Warrants (NUVB.WS) are listed on the NYSE.